Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Lovo"


3 mentions found


They claim AI stole their voices. Now they’re suing
  + stars: | 2024-05-17 | by ( Clare Duffy | ) edition.cnn.com   time to read: +3 min
Now, Lehrman, along with fellow voice actor Linnea Sage, is suing AI firm Lovo for allegedly commissioning them for voice projects under false pretenses in order to create and sell AI-generated versions of their voices. The Berkeley, California based tech company advertises AI-generated voice technology to be used in marketing, education and product demos. Then in June 2023, Lehrman claims he heard his voice being used on a podcast about the dangers of AI technologies. Sage says she later also discovered her voice in a YouTube video: a recording of a Lovo investor presentation demonstrating its technology. They are voices stolen by LOVO and marketed by LOVO under false pretenses,” the complaint states.
Persons: Paul Lehrman, Linnea Sage, Lovo, Sage, ” Lovo, Lehrman, he’d, LOVO Organizations: New, New York CNN —, Court, New York Times Locations: New York, Berkeley, California, Southern
Here are Friday's biggest calls on Wall Street: Bank of America upgrades Hasbro to neutral from underperform Bank of America said it sees resilient demand for Hasbro . Goldman Sachs reiterates Amazon as buy Goldman said it's standing by the stock after its robust earnings report Thursday. " Benchmark upgrades Intel to buy from hold Benchmark said in its upgrade of Intel that the worst is already baked in. Bank of America upgrades Pilgrim's Pride to buy from neutral Bank of America said in its upgrade of the poultry company that the worst is behind it. Morgan Stanley reiterates Apple as overweight Morgan Stanley said it's still bullish on Apple shares heading into earnings next week.
Shares of biotech company bluebird bio should double in the coming year, thanks to its treatments for sickle cell disease, a genetic blood disease and a rare genetic brain condition, according to Baird. The Wall Street firm initiated coverage of the stock on Monday with an outperform rating and $10 price target, which implies 104% upside from Monday's close. The company's management said in January that 40 patients had initiated benefits verification for Zynteglo during the last three months of 2022. Lastly, Baird expects the use of bluebird's Skysona treatment for CALD, which was approved in September 2022, to increase significantly in the coming years. The under-the-radar stock, which has a market cap of over $500 million, is down about 29% this year, as of Monday's close.
Total: 3